Differences in the Intestinal Microbiome Associated with Diarrhea during Lenvatinib Treatment for Hepatocellular Carcinoma

INTRODUCTION: Lenvatinib has been widely used for the treatment of advanced hepatocellular carcinoma (HCC). Some adverse events, including diarrhea, have been reported for lenvatinib. Diarrhea may be associated with the changes in the intestinal microbiome; however, the underlying mechanism has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Inukai, Yosuke, Yamamoto, Kenta, Honda, Takashi, Ito, Takanori, Imai, Norihiro, Ishizu, Yoji, Nakamura, Masanao, Kawashima, Hiroki, Ishigami, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Microbiota: Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909711/
https://www.ncbi.nlm.nih.gov/pubmed/35344958
http://dx.doi.org/10.1159/000524298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909711/
https://www.ncbi.nlm.nih.gov/pubmed/35344958
http://dx.doi.org/10.1159/000524298

Ejemplares similares